Skip to main content

High Fusion Inc. (2NU.F)

FSX Healthcare Drug Manufacturers - Specialty & GenericView data quality →
27.1Poor

ValueMarkers Composite Index

Top 0%#44,687 of 44,714

DCF data not available

Piotroski
0/9
Weak
Beneish
-
Altman
-
DCF Value
-
N/A
ROIC
-121.4%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

High Fusion Inc. (2NU.F) — VMCI valuation read

Across 120 indicators, High Fusion Inc. (2NU.F) lands at VMCI 27/100. The Healthcare sector median is 50, so the 23-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 2NU.F in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 2NU.F trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of 3.0x is the rate-sensitivity line to watch for 2NU.F on the trailing balance sheet.

2NU.F fell 1.0% over the trailing 7 days, with a -22.9% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 2NU.F’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.